Search research articles
Contact Us
Filters
Showing results (31-40 of 74) with videos related to
Page
of 8
Sort By:
Blood
|
March 19, 2011
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
Hugo F Fernandez, Zhuoxin Sun, Mark R Litzow, et al.
British Journal of Haematology
|
April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study
Roland B Walter, Hagop M Kantarjian, Xuelin Huang, et al.
Leukemia Research
|
January 24, 2019
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)
Bruno C Medeiros, Megan Othus, Martin S Tallman, et al.
Clinical Lung Cancer
|
July 26, 2022
A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181
John Michael Varlotto, Zhuoxin Sun, Bonnie Ky, et al.
Blood
|
July 1, 2009
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Peter L Greenberg, Zhuoxin Sun, Kenneth B Miller, et al.
Breast (Edinburgh, Scotland)
|
April 14, 2010
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
Kelly-Anne Phillips, Karin Ribi, Zhuoxin Sun, et al.
Breast Cancer Research and Treatment
|
November 4, 2010
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
Kelly-Anne Phillips, Julie Aldridge, Karin Ribi, et al.
British Journal of Haematology
|
July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Blood
|
August 3, 2012
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900
Mithat Gönen, Zhuoxin Sun, Maria E Figueroa, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 74) with videos related to
Sort By:
Page
of 8
Blood
|
March 19, 2011
Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
Hugo F Fernandez, Zhuoxin Sun, Mark R Litzow, et al.
British Journal of Haematology
|
April 10, 2014
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 18, 2010
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study
Roland B Walter, Hagop M Kantarjian, Xuelin Huang, et al.
Leukemia Research
|
January 24, 2019
The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900)
Bruno C Medeiros, Megan Othus, Martin S Tallman, et al.
Clinical Lung Cancer
|
July 26, 2022
A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181
John Michael Varlotto, Zhuoxin Sun, Bonnie Ky, et al.
Blood
|
July 1, 2009
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Peter L Greenberg, Zhuoxin Sun, Kenneth B Miller, et al.
Breast (Edinburgh, Scotland)
|
April 14, 2010
Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial
Kelly-Anne Phillips, Karin Ribi, Zhuoxin Sun, et al.
Breast Cancer Research and Treatment
|
November 4, 2010
Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial
Kelly-Anne Phillips, Julie Aldridge, Karin Ribi, et al.
British Journal of Haematology
|
July 5, 2014
Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS
Amer M Zeidan, Ju-Whei Lee, Thomas Prebet, et al.
Blood
|
August 3, 2012
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900
Mithat Gönen, Zhuoxin Sun, Maria E Figueroa, et al.
Page
of 8